1. Cytocompatible dendrimer G3.0-hematin nanoparticle with high stability and solubility for mimicking horseradish peroxidase activity in in-situ forming hydrogel.
- Author
-
Nguyen VT, Le TP, Dang LH, Ton TP, Nguyen DT, Dang NN, Nguyen BT, Van Van V, Nguyen TH, and Tran NQ
- Subjects
- Cell Line, Horseradish Peroxidase chemistry, Horseradish Peroxidase pharmacology, Humans, Biomimetic Materials chemistry, Biomimetic Materials pharmacology, Dendrimers chemistry, Dendrimers pharmacology, Fibroblasts metabolism, Hemin chemistry, Hemin pharmacology, Materials Testing, Nanoparticles chemistry
- Abstract
Hematin has been used as an alternative enzyme catalyst to horseradish peroxidase (HRP) due to its iron-containing activity center. Although hematin and it derivatives have been widely used for polymerization of phenol/analine compounds, it has some drawbacks such as the limited solubility and reaction only at high pH condition. Herein, we report a nanosized biomimetic catalyst, hematin-decorated polyamidoamine dendrimer (G3.0-He) that can effectively catalyze the in situ hydrogelation of phenol-conjugated polymers under neutral pH condition. We demonstrate that G3.0-He particles are smaller than 100 nm and have excellent enzyme-mimetic functions. Interestingly, the nanosized catalyst is not inactivated at high H
2 O2 concentration. Compared to pure hematin, G3.0-He has significantly higher dispersion in acidic and neutral media, and preserves the percentage of survival of fibroblasts over 90%. Notably, G3.0-He possesses an exquisite HRP-mimicking activity in gelation of gelatin derivative with phenolic hydroxyl (tyamine) moieties under mild physiological conditions. The in vitro study demonstrated that Gel-Tyr hydrogel by G3.0-He catalyzed reaction had excellent cytocompatibility and an excellent scaffold for adhesion to fibroblast cells. Therefore, the designed minimalistic G3.0-He catalyst could serve as an effective catalytic alternative for HRP enzyme in the preparation of biomedical hydrogels., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF